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Role of echocardiography and platelet scintigraphy
in the diagnosis of ventricular thrombi. It has long been
recognized that the left ventricle is an important source of
systemic embolization; however, it was not until recently
that the direct recognition of left ventricular thrombi was
possible. As Visser and his colleagues ( I) in this issue of
the Journal indicate echocardiography is a valuable tool for
the diagnosis of ieft ventricular thrombi in the setting of
acute infarction. It is a noninvasive method and may be
performed at the bedside. Initial studies using M-mode echo-
cardiography were disappointing because this technique does
not routinely examine the cardiac apex , where the over-
whelming majority of left ventricular thrombi occur. Early
studies (2-4) using two-dimensional echocardiography ,
however , demonstrated that it affords a major advantage
over the M-mode technique because the cardiac apex may
be viewed from a number of transducer positions. Echo-
cardiography identifies a mass lesion and does not provide
a direct index of thrombus activity. For this reason, a second
technique using indium-Ill-labeled platelets was developed.
Indium-Ill has physical characteristics suitable for im-
aging. The St. Louis group (6) were the first to demonstrate
that when 8-0H quinoline was chelated with indium-Ill ,
a lipid-soluble complex is formed that is internalized within
the platelet cytoplasm and permanently labels human plate-
lets without altering physiologic function. This technique
depend s entirely on the active exchange of platelets at the
blood thrombus interface and, therefore, not only identifies
the thrombus but also reflects its activity (6). Several studies
(7-9) have been performed to define the accuracy of both
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echocardiography and platelet scintigraphy. These have been
prospective studies and have used findings at aneurysmec-
tomy or autopsy as reference standards. In one echocardio-
graphic study (8) , platelet scintigraphy, because of its high
specificity, was used as the reference standard in those cases
where tissue confirmation could not be obtained.
Advantages and disadvantages . For echocardiography,
sensitivity varies from 92 to 77% and specificity from 94
to 84% (7-9) . It is estimated that up to 25% of studies may
be technically inadequate (9). Thus , echographic quality
provides the major limitation of this technique. Platelet scin-
tigraphy has a specificity that approaches 100% (9,10). In
patients with a chronic left ventricular aneurysm, scintig-
raphy has a lower sensitivity (71%) (9). This finding relates
directly to the activity of the thrombus . For thrombi de-
veloping during acute infarction , there is indirect evidence
that platelet scintigraphy has a higher sensitivity because
the incidence of thrombi by scintigraphy is close to that
found at autopsy (10) . The major disadvantage of platelet
scintigraphy is that 90 minutes is required for platelet la-
beling and the diagnosis is reliable only after 48 to 96 hours
after injection of the platelet suspension. This is mainly due
to the high background activity derived from the circulating
platelets that preclude target to background ratios suitable
for earlier thrombus detection. To obviate this difficulty ,
background subtraction (11) and tomographic imaging tech-
niques (12) have been employed. These, however, are cum-
bersome, especially when used in acutely ill patients. The
use of platelet-specific antibodies and the potential for ma-
nipulating the background activity holds the greatest hope
for the early recognition of ventricular thrombi and promises
broader clinical application of this technique (13,14).
In summary, echocardiography should be the first tech-
nique used to identify a left ventricular thrombus in acute
infarction. Examination should be performed by day 3 and
repeated On about day 10 if the initial study is negative . If
the examination is technically inadequate or inconclusive,
platelet scintigraphy may then be employed. Since the half-
life of the isotope and injected platelets allows imaging for
5 to 7 days, a single injection of the labeled platelet is
adequate . Insofar as monitoring efficacy of therapy is con-
cerned , platelet scintigraphy may be used investigationally
but does not , as yet, have a proven clinical role .
Clinical relevance of ventricular thrombi. These stud-
ies raise important questions concerning the clinical rele-
vance of identifying a left ventricular thrombus. It has be-
come clear that a ventricular thrombus is rare in patients
with inferior infarction and in patients with subendocardial
infarction; therefore , questions of therapy should be limited
to those patients who have sustained an acute transmural
anterior myocardial infarction (9,15,17). As Visser et al.
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to embolization, and the effect of various forms of anti-
coagulant therapy can only be truly addressed in a random-
ized prospective study. A trial of this type should involve
both echocardiography and platelet scintigraphy, be per-
formed in several centers to achieve an adequate sample
size and take into consideration the current enthusiasm for
employing thrombolytic therapy during the acute phase of
myocardial infarction. Thrombolytic agents may influence
the development of ventricular thrombi by a direct effect
on the thrombus and also by salvaging myocardium, thereby
causing less regional left ventricular dysfunction and, thus,
less local stasis. This latter benefit may also be seen with
pharmacologic and surgical therapy. Therefore, recommen-
dations concerning therapy must be tempered by the fact
that the definitive study in the context of today's medicine
has not been performed. Most authors agree that emboli
tend to occur early (18), within the first 6 months, and most
trials (19,20) support treatment with anticoagulants when
embolism is the end point. Successful treatment of thrombi
m~y be more difficult to assess because the effect may be
seen by scintigraphy and not by echocardiography (2l); in
addition, thrombi tend to be spontaneously evenescent.
Echocardiography may, as Visser et al. have shown, pin-
point protruberant thrombi that are more likely to embolize.
Recommendations. Until a prospectiverandomized study
is completed, it is reasonable to conclude that patients with
anterior myocardial infarction and a ventricular thrombus
(particularly if the thrombus is protruberant), unless im-
portant contraindicationsto anticoagulanttherapy exist, should
receive intravenous heparin on presentation followed by 6
months of Coumadin therapy. This obviously implies care-
ful and regular monitoring of anticoagulant therapy. One
can argue, based on the older literature, that all patients
with transmural anterior myocardial infarction in whom a
thrombus cannot be reasonably exluded should be antico-
agulated. In these patients, the probability ofembolism should
be carefully weighed against the danger of bleeding. If the
probability' of a major complication is low, it is not unrea-
sonable to advise anticoagulation therapy.
I thank John R. Stratton, MD and Richard W. Asinger, MD for their
valuable comments.
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